Floatz logo

Therapeutic Asset Ratings

188 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Atezolizumab
Prostatic Neoplasms, Castration-Resistant
Cancer Research UKP3BB (66)
VEMURAFENIB
Melanoma
Cancer Research UKP3BB (66)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Haematological Malignancy
Cancer Research UKP2/3BB (66)
gsk1120212
Cancer
Cancer Research UKP2/3BB (65)
Atezolizumab
Haematological Malignancy
Cancer Research UKP2/3BB (64)
Entrectinib
Haematological Malignancy
Cancer Research UKP2/3BB (64)
TRASTUZUMAB
Gallbladder Neoplasms
Cancer Research UKP2/3BB (64)
TRASTUZUMAB
Haematological Malignancy
Cancer Research UKP2/3BB (64)
ALECTINIB
Haematological Malignancy
Cancer Research UKP2/3B (62)
Atezolizumab
Colorectal Neoplasms
Cancer Research UKP2/3B (62)
Cobimetinib
Haematological Malignancy
Cancer Research UKP2/3B (62)
Dabrafenib
Haematological Malignancy
Cancer Research UKP2/3B (62)
gsk1120212
Haematological Malignancy
Cancer Research UKP2/3B (62)
TRASTUZUMAB
Lung Neoplasm
Cancer Research UKP2/3B (62)
VEMURAFENIB
Haematological Malignancy
Cancer Research UKP2/3B (62)
gsk1120212
Solid Tumors
Cancer Research UKP4B (61)
gsk1120212
ATC
Cancer Research UKP2/3B (61)
gsk1120212
Non-Melanoma Skin Cancer (NMSC)
Cancer Research UKP2/3B (61)
Dabrafenib
NSCLC
Cancer Research UKP4B (60)
ALECTINIB
Neoplasms
Cancer Research UKP3B (60)
Dabrafenib
Cancer
Cancer Research UKP3B (60)
TRASTUZUMAB
Colorectal Neoplasms
Cancer Research UKP3B (60)
Dabrafenib
Non-Melanoma Skin Cancer (NMSC)
Cancer Research UKP2/3B (60)
Atezolizumab
Sarcoma
Cancer Research UKP2B (59)
gsk1120212
Gastrointestinal Cancer
Cancer Research UKP2/3B (59)
Showing 1 to 25 of 188 assets
PreviousPage 1 of 8Next